Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1571-1572, 2005; 10.1373/clinchem.2005.053405
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Semmes, O. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Semmes, O. J.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2005;51:1571-1572.)
© 2005 American Association for Clinical Chemistry, Inc.

Editorials

The "omics" Haystack: Defining Sources of Sample Bias in Expression Profiling

O. John Semmes

Department of Microbiology and Molecular Cell Biology, Center for Biomedical Proteomics, Virginia Prostate Center, Eastern Virginia Medical School, 700 W. Olney Road, Norfolk, VA 23508, E-mail semmesoj@evms.edu

The first 20% of the full text of this article appears below.

Great medical benefit may result from biomarker discovery, but the scarcity of useful biomarkers among myriad genes and proteins makes this task every bit as daunting as finding the needle in a haystack. At the moment we are not even certain what the needle or the haystack looks like (although many of us are certain we know one when we see one) or, more precisely, how to separate the signal from the noise. The need for better disease management tools has placed considerable demand on the scientific community to find appropriate clinical biomarkers, ushering in the "omics" era—the application of specific technologies such as proteomics, genomics, and metabolomics along with the mainstreaming of high-throughput, high-volume analytical approaches.

Clearly the development and implementation of novel technologies as well as innovative new application of "old" technologies is justified. However, this pushing of the technical envelope must be balanced with careful scientific evaluation of the performance characteristics of each new paradigm. The collision of these two imperatives has never been more apparent than in the current debate over protein expression profiling and pattern recognition–based diagnostics. The opposing forces of excitement associated with innovation (1)(2) and caution regarding . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Mol. Cell. ProteomicsHome page
R. R. Drake, E. E. Schwegler, G. Malik, J. Diaz, T. Block, A. Mehta, and O. J. Semmes
Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers
Mol. Cell. Proteomics, October 1, 2006; 5(10): 1957 - 1967.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.